| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE44638 | GILEAD SCIENCES INC | Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta |
Aug, 2025
(1 year, 10 months from now) | |
| US8865730 | GILEAD SCIENCES INC | Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one |
Mar, 2033
(9 years from now) | |
| US10730879 | GILEAD SCIENCES INC | Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one |
Mar, 2033
(9 years from now) | |
| US9469643 | GILEAD SCIENCES INC | Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one |
Sep, 2033
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8980901 | GILEAD SCIENCES INC | 5-fluoro-3-phenyl-2[1-(9H-purin-6-ylamino)propyl]-3H-quinazolin-4-one and 6-fluoro-3-phenyl-2-[1-(9H-purin-6-ylamino)ethyl]-3H-quinazolin-4-one as inhibitors of human phosphatidylinositol 3-kinase delta |
May, 2025
(1 year, 7 months from now) | |
| US9149477 | GILEAD SCIENCES INC | 5-fluoro-3-phenyl-2-[1-(9h-purin-6-ylamino)propyl]-3h-quinazolin-4-one as an inhibitor of human phosphatidylinositol 3-kinase delta |
May, 2025
(1 year, 7 months from now) | |
| USRE44599 | GILEAD SCIENCES INC | Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta |
Jul, 2025
(1 year, 9 months from now) | |
| US9492449 | GILEAD SCIENCES INC | Therapies for hematologic malignancies |
Mar, 2030
(6 years from now) | |
Zydelig is owned by Gilead Sciences Inc.
Zydelig contains Idelalisib.
Zydelig has a total of 8 drug patents out of which 0 drug patents have expired.
Zydelig was authorised for market use on 23 July, 2014.
Zydelig is available in tablet;oral dosage forms.
Zydelig can be used as in combination with rituximab, for the treatment of patients with relapsed chronic lymphocytic leukemia (cll), inhibition on pi3k kinase, for the treatment of patients with cll, fl, or sll, for the treatment of patients with cll, fl, or sll; for the treatment of patients with relapsed follicular b-cell non-hodgkin lymphoma or [relapsed] small lymphocytic lymphoma.
The generics of Zydelig are possible to be released after 02 September, 2033.
Drugs and Companies using IDELALISIB ingredient
Market Authorisation Date: 23 July, 2014
Treatment: For the treatment of patients with cll, fl, or sll; Inhibition on pi3k kinase; For the treatment of patients with relapsed follicular b-cell non-hodgkin lymphoma or [relapsed] small lymphocytic lympho...
Dosage: TABLET;ORAL
ZYDELIG family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic